抗生物質耐性の市場規模、シェア、動向分析レポート：疾患別、病原体別、薬剤クラス別、作用機序別、流通チャネル別、地域別、セグメント予測、2024年～2030年

抗生物質耐性市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の抗生物質耐性市場規模は2024年から2030年にかけてCAGR 5.27％を記録し、2030年には124億8,000万米ドルに達すると予測されています。

抗生物質の誤用や過剰使用による抗生物質耐性感染症の増加が市場成長の主な要因です。さらに、世界中で患者数が増加しており、病気の治療に関連するコストが高いことが、予測期間中の市場成長を押し上げると予測されています。

グラム陰性感染症の流行は憂慮すべき速度で増加しています。これらの感染症は、市場で利用可能な治療選択肢が少ないです。アンメットニーズが高いため、新しい治療法に対する需要も高く、そのため中小規模の製薬会社は新規治療法の開発に積極的に取り組んでいます。さらに、政府やその他の機関も革新的な治療法の開発を推進するために研究活動を支援しています。

複数の中堅バイオテクノロジー企業が、抗生物質耐性感染症の標的治療薬でこの分野に参入しています。様々なメーカーが、特に薬剤耐性感染症向けに、より少数の人々を対象とした治療法を開発しています。

米国政府はBARDAとの提携により、抗生物質耐性疾患に対する新しい治療法の開発を後押しするため、いくつかの企業を支援しています。BARDAは、GSK、テトラフェーズ、バシレア、アストラゼネカなどの製薬会社とも提携しています。多くの国や国際機関が、薬剤耐性感染症のパターンを監視・研究するための専門グループやアライアンスを結成しています。

例えば、WHOは世界抗菌薬耐性サーベイランスシステム（Global Antimicrobial Resistance Surveillance System：GLASS）を導入し、抗生物質耐性感染症を世界レベルで監視しています。同様に、カナダ公衆衛生局は、国レベルでの薬剤耐性感染パターンを調査するためにカナダ抗菌薬耐性サーベイランスシステム（CARSS）を導入しています。

しかし、WHOが2023年3月に発表したレビューによると、抗生物質のパイプライン活動は限られており、2017年から2021年の間に承認された新しい抗生物質はわずか12種類に過ぎないです。このレビューではさらに、開発中の新規候補薬は27種類に過ぎず、そのうちWHOが定義する抗生物質耐性を克服できるほど「革新的」と考えられるものは6種類に過ぎないとしています。

抗生物質耐性市場レポートハイライト

• 2023年には、cUTIが最大の市場シェアを占め、今後数年間も世界市場での優位性を維持すると予測されます。
• 配合剤は予測期間中最も速いCAGRで成長すると予測されます。
• 北米は2023年に抗生物質耐性産業を支配しました。耐性グラム陽性および陰性感染症の重大な負担に対応するため、米国国家行動計画によって設定された目標目標が市場を牽引する主な要因です。
• アジア太平洋は、抗生物質の過剰消費、技術の進歩、抗生物質耐性検査・治療・管理に関する意識の高まりにより、予測期間中に最も速い成長を示すことになります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗生物質耐性の市場変数、動向および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 抗生物質耐性市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 抗生物質耐性市場：疾患の推定・動向分析

• 疾病市場シェア、2023年と2030年
• セグメントダッシュボード
• 疾患別の世界の抗生物質耐性市場の見通し
• 以下の市場規模、予測および動向分析、2018年から2030年まで

第5章 抗生物質耐性市場：病原推定・動向分析

• 病原体市場シェア、2023年および2030年
• セグメントダッシュボード
• 病原体別の世界の抗生物質耐性市場の見通し
• 以下の市場規模、予測および動向分析、2018年から2030年まで

第6章 抗生物質耐性市場：薬剤クラスの推定・動向分析

• 医薬品クラスの市場シェア、2023年と2030年
• セグメントダッシュボード
• 薬剤クラス別の世界の抗生物質耐性市場の見通し
• 以下の市場規模、予測および動向分析、2018年から2030年まで

第7章 抗生物質耐性市場：作用推定・動向分析

• アクションのメカニズム市場シェア、2023年と2030年
• セグメントダッシュボード
• 作用機序別の世界の抗生物質耐性市場の見通し
• 以下の市場規模、予測および動向分析、2018年から2030年まで

第8章 抗生物質耐性市場：流通チャネルの推定・動向分析

• 流通チャネル市場シェア、2023年と2030年
• セグメントダッシュボード
• 流通チャネル別の世界の抗生物質耐性市場の見通し
• 以下の市場規模、予測および動向分析、2018年から2030年まで

第9章 抗生物質耐性市場：地域推定・動向分析

• 地域市場シェア分析、2023年および2030年
• 地域市場ダッシュボード
• 世界の地域市場のスナップショット
• 市場規模と予測トレンド分析、2018年から2030年：
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第10章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 会社/競合の分類
• ベンダー情勢
  • List of key distributors and channel partners
  • Key customers
  • Key company market share analysis, 2023
  • Melinta Therapeutics
  • Basilea Pharmaceutica Ltd.
  • Tetraphase Pharmaceuticals
  • Theravance Biopharma
  • WOCKHARDT
  • Paratek Pharmaceuticals, Inc.
  • Seres Therapeutics
  • ACHAOGEN, INC.
  • Entasis therapeutics
  • AbbVie
  • Merck &Co. Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America Antibiotic Resistance market, by region, 2018 - 2030 (USD Million)
• Table 3 North America Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 4 North America Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 5 North America Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 6 North America Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 7 North America Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 8 U.S. Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 9 U.S. Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 10 U.S. Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 11 U.S. Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 12 U.S. Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 13 Canada Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 14 Canada Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 15 Canada Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 16 Canada Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 17 Canada Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 18 Europe Antibiotic Resistance market, by region, 2018 - 2030 (USD Million)
• Table 19 Europe Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 20 Europe Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 21 Europe Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 22 Europe Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 23 Europe Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24 Germany Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 25 Germany Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 26 Germany Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 27 Germany Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 28 Germany Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 29 UK Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 30 UK Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 31 UK Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 32 UK Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 33 UK Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 34 France Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 35 France Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 36 France Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 37 France Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 38 France Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 39 Italy Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 40 Italy Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 41 Italy Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 42 Italy Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 43 Italy Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 44 Spain Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 45 Spain Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 46 Spain Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 47 Spain Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 48 Spain Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 49 Denmark Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 50 Denmark Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 51 Denmark Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 52 Denmark Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 53 Denmark Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 54 Sweden Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 55 Sweden Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 56 Sweden Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 57 Sweden Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 58 Sweden Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 59 Norway Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 60 Norway Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 61 Norway Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 62 Norway Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 63 Norway Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific Antibiotic Resistance market, by region, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 66 Asia Pacific Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 67 Asia Pacific Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 68 Asia Pacific Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 69 Asia Pacific Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 70 China Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 71 China Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 72 China Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 73 China Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 74 China Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 75 Japan Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 76 Japan Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 77 Japan Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 78 Japan Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 79 Japan Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 80 India Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 81 India Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 82 India Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 83 India Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 84 India Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 85 South Korea Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 86 South Korea Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 87 South Korea Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 88 South Korea Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 89 South Korea Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90 Australia Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 91 Australia Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 92 Australia Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 93 Australia Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 94 Australia Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 95 Thailand Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 96 Thailand Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 97 Thailand Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 98 Thailand Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 99 Thailand Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 100 Latin America Antibiotic Resistance market, by region, 2018 - 2030 (USD Million)
• Table 101 Latin America Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 102 Latin America Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 103 Latin America Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 104 Latin America Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 105 Latin America Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 106 Brazil Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 107 Brazil Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 108 Brazil Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 109 Brazil Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 110 Brazil Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 111 Mexico Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 112 Mexico Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 113 Mexico Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 114 Mexico Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 115 Mexico Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 116 Argentina Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 117 Argentina Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 118 Argentina Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 119 Argentina Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 120 Argentina Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 121 MEA Antibiotic Resistance market, by region, 2018 - 2030 (USD Million)
• Table 122 MEA Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 123 MEA Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 124 MEA Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 125 MEA Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 126 MEA Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 127 South Africa Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 128 South Africa Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 129 South Africa Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 130 South Africa Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 131 South Africa Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 132 Saudi Arabia Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 133 Saudi Arabia Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 134 Saudi Arabia Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 135 Saudi Arabia Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 136 Saudi Arabia Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 137 UAE Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 138 UAE Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 139 UAE Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 140 UAE Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 141 UAE Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
• Table 142 Kuwait Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
• Table 143 Kuwait Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
• Table 144 Kuwait Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
• Table 145 Kuwait Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
• Table 146 Kuwait Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)  

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Antibiotic Resistance market: market outlook
• Fig. 14 Antibiotic Resistance competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Antibiotic Resistance market driver impact
• Fig. 20 Antibiotic Resistance market restraint impact
• Fig. 21 Antibiotic Resistance market strategic initiatives analysis
• Fig. 22 Antibiotic Resistance market: Disease movement analysis
• Fig. 23 Antibiotic Resistance market: Disease outlook and key takeaways
• Fig. 24 cUTI Antibiotic Resistance market estimates and forecast, 2018 - 2030
• Fig. 25 CDI Antibiotic Resistance market estimates and forecast, 2018 - 2030
• Fig. 26 ABSSSI Antibiotic Resistance market estimates and forecast, 2018 - 2030
• Fig. 27 HABP Antibiotic Resistance market estimates and forecast, 2018 - 2030
• Fig. 28 CABP Antibiotic Resistance market estimates and forecast, 2018 - 2030
• Fig. 29 cIAI Antibiotic Resistance market estimates and forecast, 2018 - 2030
• Fig. 30 BSI Antibiotic Resistance market estimates and forecast, 2018 - 2030
• Fig. 31 Antibiotic Resistance Market: Pathogen movement Analysis
• Fig. 32 Antibiotic Resistance market: Pathogen outlook and key takeaways
• Fig. 33 E. coli market estimates and forecasts, 2018 - 2030
• Fig. 34 K. pneumoniae market estimates and forecasts,2018 - 2030
• Fig. 35 P. aeruginosa market estimates and forecasts, 2018 - 2030
• Fig. 36 S. aureus market estimates and forecasts,2018 - 2030
• Fig. 37 A. baumannii market estimates and forecasts, 2018 - 2030
• Fig. 38 S. pneumoniae market estimates and forecasts,2018 - 2030
• Fig. 39 H. influenzae market estimates and forecasts, 2018 - 2030
• Fig. 40 C. difficile market estimates and forecasts,2018 - 2030
• Fig. 41 E. faecium market estimates and forecasts, 2018 - 2030
• Fig. 42 Antibiotic Resistance market: Drug Class movement analysis
• Fig. 43 Antibiotic Resistance market: Drug Class outlook and key takeaways
• Fig. 44 Oxazolidinones market estimates and forecasts, 2018 - 2030
• Fig. 45 Lipoglycopeptides market estimates and forecasts,2018 - 2030
• Fig. 46 Tetracyclines market estimates and forecasts,2018 - 2030
• Fig. 47 Combination therapies market estimates and forecasts,2018 - 2030
• Fig. 48 Cephalosporins market estimates and forecasts,2018 - 2030
• Fig. 49 Others market estimates and forecasts,2018 - 2030
• Fig. 50 Antibiotic Resistance market: Mechanism of Action movement analysis
• Fig. 51 Antibiotic Resistance market: Mechanism of Action outlook and key takeaways
• Fig. 52 Protein Synthesis Inhibitors market estimates and forecasts, 2018 - 2030
• Fig. 53 Cell Wall Synthesis Inhibitors market estimates and forecasts,2018 - 2030
• Fig. 54 RNA Synthesis Inhibitors market estimates and forecasts, 2018 - 2030
• Fig. 55 DNA Synthesis Inhibitors market estimates and forecasts,2018 - 2030
• Fig. 56 Others Inhibitors market estimates and forecasts,2018 - 2030
• Fig. 57 Antibiotic Resistance market: Distribution Channel movement analysis
• Fig. 58 Antibiotic Resistance market: Distribution Channel outlook and key takeaways
• Fig. 59 Hospital Pharmacies market estimates and forecasts, 2018 - 2030
• Fig. 60 Retail Pharmacies market estimates and forecasts,2018 - 2030
• Fig. 61 Online Pharmacies market estimates and forecasts,2018 - 2030
• Fig. 62 Global Antibiotic Resistance market: Regional movement analysis
• Fig. 63 Global Antibiotic Resistance market: Regional outlook and key takeaways
• Fig. 64 Global Antibiotic Resistance market share and leading players
• Fig. 65 North America market share and leading players
• Fig. 66 Europe market share and leading players
• Fig. 67 Asia Pacific market share and leading players
• Fig. 68 Latin America market share and leading players
• Fig. 69 Middle East & Africa market share and leading players
• Fig. 70 North America: SWOT
• Fig. 71 Europe SWOT
• Fig. 72 Asia Pacific SWOT
• Fig. 73 Latin America SWOT
• Fig. 74 MEA SWOT
• Fig. 75 North America
• Fig. 76 North America market estimates and forecasts, 2018 - 2030
• Fig. 77 U.S.
• Fig. 78 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 79 Canada
• Fig. 80 Canada market estimates and forecasts, 2018 - 2030
• Fig. 81 Europe
• Fig. 82 Europe market estimates and forecasts, 2018 - 2030
• Fig. 83 UK
• Fig. 84 UK market estimates and forecasts, 2018 - 2030
• Fig. 85 Germany
• Fig. 86 Germany market estimates and forecasts, 2018 - 2030
• Fig. 87 France
• Fig. 88 France market estimates and forecasts, 2018 - 2030
• Fig. 89 Italy
• Fig. 90 Italy market estimates and forecasts, 2018 - 2030
• Fig. 91 Spain
• Fig. 92 Spain market estimates and forecasts, 2018 - 2030
• Fig. 93 Denmark
• Fig. 94 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 95 Sweden
• Fig. 96 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 97 Norway
• Fig. 98 Norway market estimates and forecasts, 2018 - 2030
• Fig. 99 Asia Pacific
• Fig. 100 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 101 China
• Fig. 102 China market estimates and forecasts, 2018 - 2030
• Fig. 103 Japan
• Fig. 104 Japan market estimates and forecasts, 2018 - 2030
• Fig. 105 India
• Fig. 106 India market estimates and forecasts, 2018 - 2030
• Fig. 107 Thailand
• Fig. 108 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 109 South Korea
• Fig. 110 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 111 Australia
• Fig. 112 Australia market estimates and forecasts, 2018 - 2030
• Fig. 113 Latin America
• Fig. 114 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 115 Brazil
• Fig. 116 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 117 Mexico
• Fig. 118 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 119 Argentina
• Fig. 120 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 121 Middle East and Africa
• Fig. 122 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 123 South Africa
• Fig. 124 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 125 Saudi Arabia
• Fig. 126 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 127 UAE
• Fig. 128 UAE market estimates and forecasts, 2018 - 2030
• Fig. 129 Kuwait
• Fig. 130 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 131 Market share of key market players- Antibiotic Resistance market

Antibiotic Resistance Market Growth & Trends:

The global antibiotic resistance market size is expected to reach USD 12.48 billion by 2030, registering a CAGR of 5.27% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rise in the number of antibiotic-resistant infections due to misuse or overuse of antibiotics is a major factor attributing to market growth. Moreover, the increasing patient base across the globe and high costs associated with the treatment of diseases is anticipated to boost the market growth over the forecast period.

The prevalence of gram-negative infections is increasing at an alarming rate. These infections have lesser treatment options available in the market. The high unmet needs result in high demand for new therapies and, therefore, small and medium-sized pharmaceutical companies are actively involved in the development of novel treatment options. Moreover, the government and other organizations are also aiding research activities to drive the development of innovative therapies.

Multiple mid-level biotechnology companies have entered the arena with targeted therapies for antibiotic-resistant infections. Various manufacturers are developing therapies, especially for drug-resistant infections, that target a smaller population subset.

The U.S. government in alliance with BARDA is supporting several companies to boost the development of new therapies for antibiotic-resistant diseases. BARDA has also been associated with pharmaceutical companies such as GSK; Tetraphase; Basilea; Astra Zeneca; and many more. Many countries and international organizations have formed dedicated groups or alliances to monitor and study the pattern of drug-resistant infections.

For instance, the WHO has introduced the Global Antimicrobial Resistance Surveillance System (GLASS) to monitor antibiotic-resistant infections at a global level. Similarly, the Public Health Agency of Canada has introduced the Canadian Antimicrobial Resistance Surveillance System (CARSS) to study drug-resistant infections pattern at the country level.

However, according to a review published by WHO in March 2023, the antibiotics pipeline activities are limited, with only 12 new antibiotics being approved between 2017 and 2021. The review further stated that there are only 27 new candidates under development, out of which only 6 are considered "innovative" enough to be capable of overcoming antibiotic resistance as defined by WHO.

Antibiotic Resistance Market Report Highlights:

• In 2023, cUTI accounted for the largest market share and is anticipated to maintain its dominance in the global market in the coming years
• Combination drugs are expected to grow at the fastest CAGR over the forecast period
• North America dominated the antibiotic resistance industry in 2023. The target goals set by the U.S. national action plan in response to the significant burden of resistant gram-positive and negative infections is the key factor driving the market
• Asia Pacific is set to witness the fastest growth over the forecast period due to excessive consumption of antibiotics, advancements in technology, and growing awareness about antibiotic resistance testing, treatment, & management of the same.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease
  • 1.2.2. Pathogen
  • 1.2.3. Drug Class
  • 1.2.4. Mechanism of Action
  • 1.2.5. Distribution Channel
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary Distribution Channels
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Distribution Channels
• 1.9. List of Primary Distribution Channels
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease
  • 2.2.2. Pathogen
  • 2.2.3. Drug Class
  • 2.2.4. Mechanism of Action
  • 2.2.5. Distribution Channel
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Antibiotic Resistance Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing burden of antibiotic-resistant infections
    • 3.2.1.2. Growing need for new antibiotic therapies
    • 3.2.1.3. Rising public health concern and awareness
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of therapeutics
• 3.3. Antibiotic Resistance Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Antibiotic Resistance Market: Disease Estimates & Trend Analysis

• 4.1. Disease Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Antibiotic Resistance Market by Disease Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. cUTI (Complicated Urinary Tract Infections)
    • 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. CDI (Clostridioides difficile Infection)
    • 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. ABSSSI (Acute bacterial skin and skin structure infections)
    • 4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. HABP (Hospital-acquired bacterial pneumonia)
    • 4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. CABP (Community-acquired pneumonia)
    • 4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.6. cIAI (Complicated intra-abdominal infection)
    • 4.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.7. BSI (Bloodstream infection
    • 4.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Antibiotic Resistance Market: Pathogen Estimates & Trend Analysis

• 5.1. Pathogen Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Antibiotic Resistance Market by Pathogen Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. E. coli
    • 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.2. K. pneumoniae
    • 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.3. P. aeruginosa
    • 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.4. S. aureus
    • 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.5. A. baumannii
    • 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.6. S. pneumoniae
    • 5.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.7. H. influenzae
    • 5.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.8. C. difficile
    • 5.4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.9. E. faecium
    • 5.4.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Antibiotic Resistance Market: Drug Class Estimates & Trend Analysis

• 6.1. Drug Class Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Antibiotic Resistance Market by Drug Class Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Oxazolidinones
    • 6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 6.4.2. Lipoglycopeptides
    • 6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.3. Tetracyclines
    • 6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.4. Combination therapies
    • 6.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.5. Cephalosporins
    • 6.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Antibiotic Resistance Market: Mechanism of Action Estimates & Trend Analysis

• 7.1. Mechanism of Action Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Antibiotic Resistance Market by Mechanism of Action Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Protein Synthesis Inhibitors
    • 7.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 7.4.2. Cell Wall Synthesis Inhibitors
    • 7.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.3. RNA Synthesis Inhibitors
    • 7.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 7.4.4. DNA Synthesis Inhibitors
    • 7.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.5. Others
    • 7.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Antibiotic Resistance Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Distribution Channel Market Share, 2023 & 2030
• 8.2. Segment Dashboard
• 8.3. Global Antibiotic Resistance Market by Distribution Channel Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Hospital Pharmacies
    • 8.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 8.4.2. Retail Pharmacies
    • 8.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.3. Online Pharmacies
    • 8.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Antibiotic Resistance Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2023 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.5. North America
  • 9.5.1. U.S.
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.2. Canada
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.6. Europe
  • 9.6.1. UK
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.2. Germany
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.3. France
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/reimbursement structure
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.4. Italy
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/reimbursement structure
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.5. Spain
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/reimbursement structure
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.6. Norway
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/reimbursement structure
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.7. Sweden
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/reimbursement structure
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.8. Denmark
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework/reimbursement structure
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Japan
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.2. China
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.3. India
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.4. Australia
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.5. South Korea
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/reimbursement structure
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.6. Thailand
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/reimbursement structure
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Brazil
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework/reimbursement structure
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.8.2. Mexico
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/reimbursement structure
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.8.3. Argentina
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework/reimbursement structure
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. South Africa
    • 9.9.1.1. Key country dynamics
    • 9.9.1.2. Regulatory framework/reimbursement structure
    • 9.9.1.3. Competitive scenario
    • 9.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.9.2. Saudi Arabia
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/reimbursement structure
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.9.3. UAE
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/reimbursement structure
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.9.4. Kuwait
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/reimbursement structure
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2023
  • 10.3.4. Melinta Therapeutics
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Disease benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Basilea Pharmaceutica Ltd.
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Disease benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Tetraphase Pharmaceuticals
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Disease benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Theravance Biopharma
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Disease benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. WOCKHARDT
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Disease benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Paratek Pharmaceuticals, Inc.
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Disease benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Seres Therapeutics
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Disease benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. ACHAOGEN, INC.
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Disease benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Entasis therapeutics
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Disease benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. AbbVie
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Disease benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Merck & Co. Inc.
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Disease benchmarking
    • 10.3.14.4. Strategic initiatives